Investment Thesis
NRX Pharmaceuticals is in severe financial distress with negative stockholders' equity of -$15.9M, indicating liabilities exceed assets. The company is burning cash at an alarming rate (-$14.1M operating cash flow) with minimal revenue ($1.2M) and massive operating losses (-$16.2M), leaving minimal runway with only $7.8M in cash.
Strengths
- Maintains $7.8M in cash reserves providing short-term liquidity
- Reduced net loss per share by 69.7% YoY through dilution management
- Minimal capital expenditure ($0) suggesting focus on preservation
Risks
- Negative stockholders' equity of -$15.9M indicates technical insolvency and potential covenant violations
- Operating cash burn of -$14.1M with only $7.8M cash implies approximately 6.6 months of runway at current burn rate
- Revenue collapsed 15.2% YoY to $1.2M while losses increased, indicating fundamental business deterioration
- Current ratio of 0.31x shows inability to cover short-term obligations
- Liabilities exceed assets by $15.9M with $9.2M long-term debt requiring refinancing
- Operating losses represent 1,324% of revenue, indicating no viable path to profitability
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Quarterly revenue trends and pipeline progress
- Covenant compliance on $9.2M long-term debt
- Operating cash flow trajectory
- Stockholders' equity recovery or further deterioration
Financial Metrics
Revenue
1.2M
Net Income
-28.6M
EPS (Diluted)
$-0.74
Free Cash Flow
-14.1M
Total Assets
13.0M
Cash
7.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,324.4%
Net Margin
-2,336.5%
ROE
N/A
ROA
-220.9%
FCF Margin
-1,152.0%
Balance Sheet & Liquidity
Current Ratio
0.31x
Quick Ratio
0.31x
Debt/Equity
N/A
Debt/Assets
223.0%
Interest Coverage
-70.54x
Long-term Debt
9.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T20:10:11.143924 |
Data as of: 2025-12-31 |
Powered by Claude AI